Todd G. Argall
Directeur Financier/CFO chez Madison Vaccines, Inc.
Profil
Todd G.
Argall is currently the Vice President-Finance at Madison Vaccines, Inc. He previously worked as the Executive Director-Investment Accounting at Brinson Partners, Inc., the Chief Financial Officer at Wind Point Advisors LLC, and the Vice President-Finance at ProCertus BioPharm, Inc. He obtained an undergraduate degree from the University of Wisconsin.
Postes actifs de Todd G. Argall
| Sociétés | Poste | Début |
|---|---|---|
Madison Vaccines, Inc.
 Madison Vaccines, Inc. Pharmaceuticals: MajorHealth Technology Madison Vaccines, Inc. develops vaccines for patients with prostate cancer. It is also developing a sensitivity test to identify those patients who will derive clinical benefit from these vaccines. The firm develops immunological therapies in patients with minimal residual disease, and for whom the mechanism of action of vaccines is ideally suited. The company was founded by Richard R. Lesniewski and Douglas G. McNeel in 2012 and is headquartered in Madison, WI. | Directeur Financier/CFO | - |
Anciens postes connus de Todd G. Argall
| Sociétés | Poste | Fin |
|---|---|---|
Wind Point Advisors LLC
 Wind Point Advisors LLC Investment ManagersFinance Wind Point Advisors LLC (Wind Point Advisors) is a private equity firm founded in 1984 by Rich Kracum and Bob Cummings. The firm is headquartered in Chicago, Illinois. | Directeur Financier/CFO | - |
| Brinson Partners, Inc. | Comptroller/Controller/Auditor | - |
ProCertus BioPharm, Inc.
 ProCertus BioPharm, Inc. Pharmaceuticals: MajorHealth Technology ProCertus BioPharm, Inc. operates as an oncology-based pharmaceutical company. Its product includes DermX, ProDermaCel, and OralX, proprietary pharmaceuticals which are designed to reduce or eliminate the side effects associated with cancer therapy. ProDermaCel will protect cancer patients from chemotherapy- and radiotherapy-induced alopecia (hair loss), DermX will prevent radiotherapy-induced dermatitis (skin burn), and OralX will protect against chemotherapy- and radiotherapy-induced oral mucositis. The company was founded by William E. Fahl and in 1997 and is headquartered in Madison, WI. | Directeur Financier/CFO | - |
Formation de Todd G. Argall
| University of Wisconsin | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 4 |
|---|---|
ProCertus BioPharm, Inc.
ProCertus BioPharm, Inc. Pharmaceuticals: MajorHealth Technology ProCertus BioPharm, Inc. operates as an oncology-based pharmaceutical company. Its product includes DermX, ProDermaCel, and OralX, proprietary pharmaceuticals which are designed to reduce or eliminate the side effects associated with cancer therapy. ProDermaCel will protect cancer patients from chemotherapy- and radiotherapy-induced alopecia (hair loss), DermX will prevent radiotherapy-induced dermatitis (skin burn), and OralX will protect against chemotherapy- and radiotherapy-induced oral mucositis. The company was founded by William E. Fahl and in 1997 and is headquartered in Madison, WI. | Health Technology |
Wind Point Advisors LLC
Wind Point Advisors LLC Investment ManagersFinance Wind Point Advisors LLC (Wind Point Advisors) is a private equity firm founded in 1984 by Rich Kracum and Bob Cummings. The firm is headquartered in Chicago, Illinois. | Finance |
| Brinson Partners, Inc. | Finance |
Madison Vaccines, Inc.
Madison Vaccines, Inc. Pharmaceuticals: MajorHealth Technology Madison Vaccines, Inc. develops vaccines for patients with prostate cancer. It is also developing a sensitivity test to identify those patients who will derive clinical benefit from these vaccines. The firm develops immunological therapies in patients with minimal residual disease, and for whom the mechanism of action of vaccines is ideally suited. The company was founded by Richard R. Lesniewski and Douglas G. McNeel in 2012 and is headquartered in Madison, WI. | Health Technology |